NOBLE Life Science Partners (NOBLE LSP), a division of Noble Capital Markets Inc. welcomes Camillo Ricordi, M.D. to its Scientific Advisory Board (SAB)
Our SAB is a strategic resource whose experience, relationships and knowledge are utilized throughout NOBLE Life Science Partners to enhance all service offerings. Through the SAB, we have access to world-class healthcare professionals for substantive advice regarding new discoveries, technologies, products, services, and developments.
On September 19th, 2017 Camillo Ricordi, M.D. joined the NOBLE SAB. Dr. Camillo Ricordi is one of the world’s leading scientists in cell transplantation. He serves as Scientific Director and Chief Academic Officer of the University of Miami Diabetes Research Institute, is responsible Head of the cGMP Human Cell Processing Facility, a NIH-funded facility, and has been its Scientific Director since 1996. He has authored over 600 scientific publications and has been awarded 11 patents as an inventor. Dr. Ricordi developed the automated method for islet cell isolation called the "Ricordi Method".
The Noble SAB was formed for the overall objective of being instrumental and impactful in the growth and expansion of the NOBLE LSP platform through highly focused, in-depth, and substantive advice with regards to new discoveries, technologies, products, services, new developments, and trends in the Medical, Biotechnology, Pharmaceutical Industry worldwide. Nathan W. Cali, Head of NOBLE LSP Investment Banking suggested that “having such an esteemed new member increases the level of scientific acumen at NOBLE LSP that will elevate and broaden the quality of scientific diligence within the cell therapy/diabetes space. Dr. Camillo’s reach and depth within the scientific community significantly expands our scientific bench.”
Dr. Camillo Ricordi – Biography
Camillo Ricordi, M.D. is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Director of the Diabetes Research Institute (DRI; www.diabetesresearch.org) and the Cell Transplant Program. Dr. Ricordi also served as Responsible Head of the Human Cell Processing Facility (1993-2014), an NIH funded cGMP (current Good Manufacturing Practices) facility that has been providing Human Cell Products for research and clinical applications at UM, in Florida and worldwide since 1993. Dr. Ricordi has also served as Co-Director of the Executive Office of Research Leadership (2001-2003) as Senior Associate Dean for Research (2003-2006) and chaired the Dean’s Research Cabinet (2006-2012) at the UM Miller School of Medicine.
In 2015 Dr. Ricordi led the UM – UHealth – JMH team that performed the first successful transplant of a bioengineered endocrine pancreas implanted within a 3D bioactive resorbable scaffold in the abdominal cavity of a recipient with a severe form of Type 1 Diabetes (BioHUB Project). The patient has been able to discontinue insulin treatment since the first month post-transplant with excellent metabolic control. This unprecedented success resulted in renewed enthusiasm for the possibility to engineer this transplant site with additional strategies to avoid the requirements for recipient immunosuppression, and has resulted in additional key collaborative efforts, from Harvard to Stanford and with other leading international centers. The same year Dr. Ricordi launched the DRI Translational Fast Track Program to Reverse Autoimmunity and Induce Immune Tolerance, which he co-leads with Dr. Jay Skyler, in collaboration with several key UM investigators, from the SCCC, the DRI, the Departments of Medicine, Surgery, Biomedical Engineering, Microbiology and Immunology, Molecular and Cellular Pharmacology and Epidemiology.
Dr. Ricordi was president of the Cell Transplant Society (1992-94), co-founder and chairman of the National Diabetes Research Coalition (Chairman 1997), co-founder and president (1999-2001) of the International Association for Pancreas and Islet Transplantation (IPITA), and a member of the council of The Transplantation Society (2002-2008). He also served on the council of the American Society of Transplant Surgeons (2000-2002), on the National Institutes of Health (NIH-NIAID) Expert Panel on clinical approaches for tolerance induction, on the FDA Biologic Response Modifiers Advisory Committee, on the NIH/NCRR Islet Cell Resources (ICRs) Executive Committee, on the NIH-NIDDK Strategic Planning Committee and on the NIH-NIAID Expert Panel on Transplantation Research. He is currently serving as Chairperson of the Clinical Islet Transplant Consortium (NIDDK-NIAID). He has also been serving on several NIH study sections, including Surgery, Anesthesia and Trauma, the General Clinical Research Centers, Small Business Innovative Research, the Immune Tolerance Network, in addition to serving as a reviewer for several international funding agencies.
Dr. Ricordi has received numerous honors and awards, including the 2001 Nessim Habif World Prize in Surgery (University of Geneva) for developing a technology that significantly contributed to the advancement of a surgical field.
About NOBLE Life Science Partners (LSP)
NOBLE Life Science Partners a division of NOBLE Capital Markets, Inc., established in 1984, is a life science investment and merchant banking boutique built upon fundamental research and scientific due diligence. Through its SAB, healthcare equity research analysts and investment bankers, NOBLE LSP combines industry and scientific knowledge to provide its clients with value-added research, advisory, investment and merchant banking services. The company has offices in Boca Raton (HQ), New York, Boston and St. Louis. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous "non-deal" corporate road shows and sector-specific conferences.
Members: FINRA, SIPC, MSRB